Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients

Bibliographic Details
Main Authors:	Eaton, C, Wells, J, Holen, I, Croucher, P, Hamdy, F
Format:	Conference item
Published:	2004

Similar Items

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
by: Eaton, C, et al.
Published: (2004)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
by: Holen, I, et al.
Published: (2002)

Role of osteoprotegerin (OPG) in cancer.
by: Holen, I, et al.
Published: (2006)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
by: Holen, I, et al.
Published: (2002)

The role of osteoprotegerin in breast and prostate cancer
by: Holen, I, et al.
Published: (2002)

OPG is a survival factor for breast- and prostate cancer cells in vitro
by: Holen, I, et al.
Published: (2002)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
by: Miles, L, et al.
Published: (2004)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
by: Holen Ingunn, et al.
Published: (2009-07-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
by: Riham Eid, et al.
Published: (2023-06-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
by: Indra Wijaya, et al.
Published: (2024-01-01)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
by: Croucher, P, et al.
Published: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
by: Shipman, C, et al.
Published: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
by: Shipman, C, et al.
Published: (2000)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
by: Waterman, E, et al.
Published: (2007)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
by: Shipman, C, et al.
Published: (2002)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
by: Chan Kai-Ming, et al.
Published: (2011-07-01)

Osteoprotegerin and the development of myeloma bone disease
by: Croucher, P, et al.
Published: (2004)

Analysis of periodontal parameteres and salivary levels of Receptor Activator of NF- κβ Ligand (RANKL) and Osteoprotegerin (OPG) in obese periodontitis patients
by: Cheema, Raheem Ramzan
Published: (2021)

Serum level of osteoprotegerin in patients with Parkinson’s disease: a preliminary study
by: Marta Piaścik-Gromada, et al.
Published: (2024-03-01)

Changes of serum osteoprotegerin level in recurrent urolithiasis
by: A. V. Savilov, et al.
Published: (2023-10-01)

Osteoprotegerin, sclerostin, and osteocalcin serum levels in thyroid disorder patients
by: F. F. Rija, et al.
Published: (2021-10-01)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
by: Croucher, P, et al.
Published: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
by: Croucher, P, et al.
Published: (2003)

Serum Osteoprotegerin Levels and the Vascular Reactivity Index in Patients with Hypertension
by: Yen-Liang Chen, et al.
Published: (2023-10-01)

The Role of procollagen type 1 amino-terminal propertied (P1NP) Cytochrome P450 (CYPs) and Osteoprotegerin (OPG) as Potential Bone function markers in Prostate Cancer Bone Metastasis
by: Yousif Pshtiwan A., et al.
Published: (2023-01-01)

Association of OPG genotypes with their serum levels in Iraqi type 2 diabetic patients
by: Diana, et al.
Published: (2022-09-01)

Association of Serum Osteoprotegerin Level With Myocardial Injury and Cardiovascular Calcification in Chronic Kidney Disease Patients
by: Kamal M. Okasha, et al.
Published: (2022-06-01)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
by: Lane Denis, et al.
Published: (2012-11-01)

Osteoprotegerin (OPG) Upregulation Activates Breast Stromal Fibroblasts and Enhances Their Pro-Carcinogenic Effects through the STAT3/IL-6 Signaling
by: Huda K. Al-Nasrallah, et al.
Published: (2022-10-01)

Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
by: Salvador Atilano-Miguel, et al.
Published: (2022-01-01)

Association between Serum Osteoprotegerin Levels and Severity of Coronary Artery Disease in Patients with Acute Myocardial Infarction
by: Yves Cottin, et al.
Published: (2021-09-01)

iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
by: Rehman, I, et al.
Published: (2012)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
by: Nyambo, R, et al.
Published: (2004)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
by: Croucher, P, et al.
Published: (2001)

Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease
by: Nikolaos P. E. Kadoglou, et al.
Published: (2022-09-01)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
by: Nyambo, R, et al.
Published: (2004)

Serum OPG and RANKL Levels as Risk Factors for the Development of Cardiovascular Calcifications in End-Stage Renal Disease Patients in Hemodialysis
by: Michalis Spartalis, et al.
Published: (2023-02-01)

Structural changes and the differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kB ligand (RANKL) in subchondral bone during the development of osteoarthritis
by: Akma Azmiera Akman,, et al.
Published: (2018)

Value of serum osteoprotegerin in the assessment of endothelial dysfunction in obesity
by: Ahmed Mohammed Shennawy, et al.
Published: (2024-04-01)

Relationship between serum osteoprotegerin and vascular calcifications in hemodialysis patients
by: Tarek Z. El Baz, et al.
Published: (2017-06-01)